Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

omega-3-acid ethyl esters 90 - capsule, soft - 1000mg - omega-3-acid ethyl esters 90 (8000001905) 1000.000000000000mg

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

alnylam netherlands b.v. - givosiran - porphyrias, Ηπατική - Διάφορα προϊόντα πεπτικής οδού και μεταβολισμού - Θεραπεία της οξεία ηπατική πορφυρία (ahp) σε ενήλικες και εφήβους ηλικίας 12 ετών και άνω.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

sanofi winthrop industrie - ινσουλίνη aspart - Σακχαρώδης διαβήτης - Φάρμακα που χρησιμοποιούνται στον διαβήτη - insulin aspart sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

sanofi winthrop industrie - isatuximab - Πολλαπλό μυέλωμα - Αντινεοπλασματικοί παράγοντες - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

blueprint medicines (netherlands) b.v. - avapritinib - Γαστροεντερικά ορμονικά στεροειδή - Άλλοι αντινεοπλασματικοί παράγοντες, αναστολείς πρωτεϊνικής κινάσης - ayvakyt is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (gist) harbouring the platelet-derived growth factor receptor alpha (pdgfra) d842v mutation.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

gilead sciences ireland uc, galapagos nv - filgotinib maleate - Αρθρίτιδα, ρευματοειδή - Ανοσοκατασταλτικά - rheumatoid arthritisjyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). jyseleca may be used as monotherapy or in combination with methotrexate (mtx). ulcerative colitisjyseleca is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

sanofi pasteur - neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid - Μηνιγγίτιδα, μηνιγγοκοκκική - Εμβόλια - menquadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w, and y. the use of this vaccine should be in accordance with available official recommendations.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

sanofi pasteur - influenza a virus subtype h1n1 haemagglutinin, recombinant, influenza a virus subtype h3n2 haemagglutinin, recombinant, influenza b virus victoria lineage haemagglutinin, recombinant, influenza b virus yamagata lineage haemagglutinin, recombinant - Γρίπη, Ανθρώπινα - Εμβόλια - supemtek is indicated for active immunization for the prevention of influenza disease in adults. supemtek should be used in accordance with official recommendations.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

alnylam netherlands b.v. - lumasiran sodium - hyperoxaluria, primary - Άλλα προϊόντα πεπτικής οδού και μεταβολισμού, - treatment of primary hyperoxaluria type 1 (ph1) in all age groups.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

seagen b.v. - tucatinib - breast neoplasms; neoplasm metastasis - Αντινεοπλασματικοί παράγοντες - tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with her2‑positive locally advanced or metastatic breast cancer who have received at least 2 prior anti‑her2 treatment regimens.